|
1
|
Everly MJ, Bloom RD, Tsai DE and Trofe J:
Posttransplant lymphoproliferative disorder. Ann Pharmacother.
41:1850–1858. 2007.
|
|
2
|
Dierickx D, Tousseyn T, De Wolf-Peeters C,
Pirenne J and Verhoef G: Management of posttransplant
lymphoproliferative disorders following solid organ transplant: an
update. Leuk Lymphoma. 52:950–961. 2011.
|
|
3
|
Caillard S, Lelong C, Pessione F and
Moulin B; French PTLD Working Group. Post-transplant
lymphoproliferative disorders occurring after renal transplantation
in adults: report of 230 cases from the French Registry. Am J
Transplant. 6:2735–2742. 2006.
|
|
4
|
Khedmat H and Taheri S: Early onset post
transplantation lymphoproliferative disorders: analysis of
international data from 5 studies. Ann Transplant. 14:74–77.
2009.
|
|
5
|
Morton M, Coupes B, Roberts SA, et al:
Epidemiology of posttransplantation lymphoproliferative disorder in
adult renal transplant recipients. Transplantation. 95:470–478.
2013.
|
|
6
|
Ghobrial IM, Habermann TM, Macon WR, et
al: Differences between early and late posttransplant
lymphoproliferative disorders in solid organ transplant patients:
are they two different diseases? Transplantation. 79:244–247.
2005.
|
|
7
|
Tsao L and Hsi ED: The clinicopathologic
spectrum of posttransplantation lymphoproliferative disorders. Arch
Pathol Lab Med. 131:1209–1218. 2007.
|
|
8
|
Kew CE II, Lopez-Ben R, Smith JK, et al:
Posttransplant lymphoproliferative disorder localized near the
allograft in renal transplantation. Transplantation. 69:809–814.
2000.
|
|
9
|
Palmer BF, Sagalowsky AI, McQuitty DA,
Dawidson I, Vazquez MA and Lu CY: Lymphoproliferative disease
presenting as obstructive uropathy after renal transplantation. J
Urol. 153:392–394. 1995.
|
|
10
|
Khedmat H and Taheri S: Characteristics
and prognosis of post-transplant lymphoproliferative disorders
within renal allograft: Report from the PTLD. Int Survey Ann
Transplant. 15:80–86. 2010.
|
|
11
|
Cosio FG, Nuovo M, Delgado L, et al: EBV
kidney allograft infection: possible relationship with a peri-graft
localization of PTLD. Am J Transplant. 4:116–123. 2004.
|
|
12
|
Caillard S, Porcher R, Provot F, et al:
Post-transplantation lymphoproliferative disorder after kidney
transplantation: report of a nationwide French registry and the
development of a new prognostic score. J Clin Oncol. 31:1302–1309.
2013.
|
|
13
|
Quinlan SC, Pfeiffer RM, Morton LM and
Engels EA: Risk factors for early-onset and late-onset
post-transplant lymphoproliferative disorder in kidney recipients
in the United States. Am J Hematol. 86:206–209. 2011.
|
|
14
|
Bakker NA, van Imhoff GW, Verschuuren EA,
et al: HLA antigens and post renal transplant lymphoproliferative
disease: HLA-B matching is critical. Transplantation. 80:595–599.
2005.
|
|
15
|
Reshef R, Vardhanabhuti S, Luskin MR, et
al: Reduction of immunosuppression as initial therapy for
posttransplantation lymphoproliferative disorder. Am J Transplant.
11:336–347. 2011.
|
|
16
|
Parker A, Bowles K, Bradley JA, et al:
Haemato-oncology Task Force of the British Committee for Standards
in Haematology and British Transplantation Society: Management of
post-transplant lymphoproliferative disorder in adult solid organ
transplant recipients - BCSH and BTS Guidelines. Br J Haematol.
149:693–705. 2010.
|
|
17
|
Svoboda J, Kotloff R and Tsai DE:
Management of patients with post-transplant lymphoproliferative
disorder: the role of rituximab. Transpl Int. 19:259–269. 2006.
|
|
18
|
Trappe R, Oertel S, Leblond V, et al;
German PTLD Study Group; European PTLD Network. Sequential
treatment with rituximab followed by CHOP chemotherapy in adult
B-cell post-transplant lymphoproliferative disorder (PTLD): the
prospective international multicentre phase 2 PTLD-1 trial. Lancet
Oncol. 13:196–206. 2012.
|
|
19
|
Trappe R, Hinrichs C, Appel U, et al:
Treatment of PTLD with rituximab and CHOP reduces the risk of renal
graft impairment after reduction of immunosuppression. Am J
Transplant. 9:2331–2337. 2009.
|
|
20
|
Foroncewicz B, Mucha K, Usiekniewicz J, et
al: Posttransplant lymphoproliferative disorder of the lung in a
renal transplant recipient treated successfully with surgery.
Transplant Proc. 38:173–176. 2006.
|
|
21
|
Moudouni SM, Tligui M, Doublet JD, Haab F,
Gattegno B and Thibault P: Lymphoproliferative disorder presenting
as a tumor of the renal allograft. Int Urol Nephrol. 38:779–782.
2006.
|
|
22
|
André N, Roquelaure B and Conrath J:
Molecular effects of cyclosporine and oncogenesis: a new model. Med
Hypotheses. 63:647–652. 2004.
|
|
23
|
Pascual J: Post-transplant
lymphoproliferative disorder - the potential of proliferation
signal inhibitors. Nephrol Dial Transplant. 22(Suppl 1): i27–i35.
2007.
|
|
24
|
Alexandru S, Gonzalez E, Grande C, et al:
Monotherapy rapamycin in renal transplant recipients with lymphoma
successfully treated with rituximab. Transplant Proc. 41:2435–2437.
2009.
|
|
25
|
DiNardo CD and Tsai DE: Treatment advances
in posttransplant lymphoproliferative disease. Curr Opin Hematol.
17:368–374. 2010.
|
